US20160279099A1 - Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions - Google Patents

Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions Download PDF

Info

Publication number
US20160279099A1
US20160279099A1 US14/953,806 US201514953806A US2016279099A1 US 20160279099 A1 US20160279099 A1 US 20160279099A1 US 201514953806 A US201514953806 A US 201514953806A US 2016279099 A1 US2016279099 A1 US 2016279099A1
Authority
US
United States
Prior art keywords
solution
postoperative
intraocular
nsaid
ketorolac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/953,806
Other languages
English (en)
Inventor
Gregory A. Demopulos
Vincent A. Florio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omeros Corp
Original Assignee
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Medical Systems Inc filed Critical Omeros Medical Systems Inc
Priority to US14/953,806 priority Critical patent/US20160279099A1/en
Assigned to OMEROS CORPORATION reassignment OMEROS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DEMOPULOS, GREGORY A., FLORIO, VINCENT A.
Publication of US20160279099A1 publication Critical patent/US20160279099A1/en
Assigned to CRG SERVICING LLC, AS ADMINISTRATIVE AGENT reassignment CRG SERVICING LLC, AS ADMINISTRATIVE AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: OMEROS CORPORATION
Priority to US15/836,772 priority patent/US20180280350A1/en
Assigned to OMEROS CORPORATION reassignment OMEROS CORPORATION RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CRG SERVICING LLC
Priority to US16/276,337 priority patent/US11234965B2/en
Priority to US17/554,842 priority patent/US20220175727A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to methods of using liquid pharmaceutical compositions including a nonsteroidal anti-inflammatory agent and an alpha-adrenergic mydriatic agent for intraocular administration during an ophthalmologic surgical procedure to inhibit postoperative inflammatory conditions.
  • Ophthalmologic surgery necessarily results in trauma to delicate intraocular structures that induces prostaglandin synthesis and the inflammatory cascade.
  • the resulting inflammation can result in the occurrence of excess inflammation and associated postoperative inflammatory conditions, particularly in subjects having a preoperative condition placing them at elevated risk for postoperative inflammatory conditions or that may experience an elevated level of surgical trauma.
  • Ocular surgery often requires the use of a physiologic irrigation solution to facilitate the procedure and to protect and maintain the physiological integrity of intraocular tissues.
  • ophthalmologic surgical procedures typically requiring irrigation solutions include cataract extraction and lens replacement and refractive lens exchange procedures, corneal transplant procedures and vitreoretinal operations and trabeculectomy procedures for glaucoma.
  • a patient's pupil must be sufficiently dilated to permit a clear operative field and to limit the trauma that can be associated with the procedure.
  • Pupil dilation mydriasis
  • the iris sphincter muscle tends to constrict (miosis), reducing the window defined by the pupil. If pupil diameter is not maintained adequately throughout the procedure, the risk of injuring structures within the eye increases and the required operating time is often prolonged. Clinically significant reductions in pupil diameter are associated with an increase in procedure-related complications, including posterior capsule tears, retained lens fragments and vitreous leaks.
  • epinephrine is a alpha- and beta-adrenergic agonist
  • phenylephrine is an alpha-1 agonist that is sometimes administered topically prior to surgery to promote mydriasis, but phenylephrine is not approved in the United States in a preservative- and bisulfite-free form for intraocular administration.
  • Ketorolac is an NSAID that is commercially available in preserved form for ocular use.
  • Acular® from Allergan® is a ketorolac tromethamine solution that includes benzalkonium chloride 0.01% as a preservative, available in 3-mL and 6-mL dropper bottles.
  • Bedford Laboratories also supplies ketorolac tromethamine in a concentrated form (15 mg or 30 mg in 1 mL or 60 mg or 300 mg in 10 mL) for injection for intravascular or intramuscular administration.
  • Allergan supplies a preservative-free 0.45% ketorolac tromethamine ophthalmic solution, which is formulated with carboxymethylcellulose sodium, sodium chloride, sodium citrate dehydrate, in individual-use vials under the tradename Acuvail®.
  • Some ophthalmic surgeons also use topical NSAIDs preoperatively in an attempt to preempt intraoperative miosis. This approach to miosis prevention is not optimal because intraoperative irrigation solution washes out preoperatively delivered agents from the areas within the eye that are bathed by the irrigation solution.
  • OMIDRIATM phenylephrine and ketorolac injection
  • Omeros Corporation is an alpha 1-adrenergic receptor agonist and nonselective cyclooxygenase inhibitor indicated for maintaining pupil size by preventing intraoperative miosis and for reducing postoperative pain.
  • OMIDRIATM is added to standard irrigation solution used during cataract surgery or intraocular lens replacement. OMIDRIATM is not currently indicated for the reduction of postoperative inflammation.
  • the present invention provides a method for inhibiting a postoperative inflammatory condition following an ophthalmologic surgical procedure.
  • the method includes identifying a subject with an elevated risk of suffering from a postoperative inflammatory condition, which identification may be made preoperatively based on a preexisting physiologic condition or characteristic, prior treatment history, or pharmacologic history, and administering intraocularly to the subject during an ophthalmologic surgical procedure a solution including a nonsteroidal anti-inflammatory drug (NSAID) and an alpha-1 adrenergic receptor agonist mydriatic agent in an intraocular irrigation carrier.
  • NSAID nonsteroidal anti-inflammatory drug
  • mydriatic agent in an intraocular irrigation carrier.
  • the NSAID and the mydriatic agent are included in the solution in amounts sufficient to maintain intraoperative pupil diameter by promoting mydriasis and inhibiting miosis, such as maintaining an intraoperative pupil diameter of at least 6.0 mm during the procedure, and a sufficient amount of the solution is administered for uptake of an amount of the NSAID in ocular tissues sufficient for inhibition of cyclooxygenases for a period of at least six hours postoperatively, thereby inhibiting the postoperative inflammatory condition.
  • the identification of an elevated risk of postoperative inflammation may occur during the procedure based on the nature of trauma incurred during the procedure.
  • the identification of an elevated risk of a postoperative inflammatory condition may be made intraoperatively and/or preoperatively.
  • Suitable NSAIDs for use in the solution administered in accordance with the present invention include flurbiprofen, suprofen, diclofenac, ketoprofen, ketorolac, indomethacin, nepafenac and bromfenac, and suitable alpha-1 adrenergic receptor agonists include phenylephrine, epinephrine, oxymetazoline and naphazoline.
  • the NSAID is ketorolac and the mydriatic agent is phenylephrine.
  • the solution includes phenylephrine at a concentration of from 240 to 720 ⁇ M and ketorolac at a concentration of from 44 to 134 ⁇ M.
  • the phenylephrine and ketorolac may be suitably included at a molar ratio of from 3:1 to 10:1 phenylephrine to ketorolac.
  • administration of the solution results in at least 85%, and preferably at least 90%, inhibition of baseline cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) activity in ocular tissues for a period of at least six hours postoperatively.
  • administration of the solution results in at least 85%, and preferably at least 90%, inhibition of baseline COX-1 and COX-2 activity in ocular tissues for a period of at least seven hours postoperatively.
  • administration of the solution results in at least 85% inhibition of baseline COX-1 and COX-2 activity in ocular tissues for a period of at least eight hours postoperatively.
  • administration of the solution results in at least 90% inhibition of baseline COX-1 and COX-2 activity in ocular tissues for a period of at least eight hours postoperatively. In still another embodiment, administration of the solution results in at least 85% inhibition of baseline COX-1 and COX-2 activity in ocular tissues for a period of at least ten hours postoperatively.
  • the method of the present invention may be used in any ophthalmologic surgical procedure associated with a risk of postoperative inflammation, including procedures requiring pupil dilation and associated with postoperative inflammation, such as cataract extraction and lens replacement, refractive lens exchange, vitrectomy, retinal photocoagulation, retinal detachment repair, macular hole repair, retroiris tumor or mass removal, posterior sclerotomy and optic neurotomy, or in connection with the inhibition of inflammatory conditions resulting from intravitreal injections.
  • the solution of the present invention is administered to irrigate intraocular tissues during the procedure, such as continuously throughout the procedure.
  • solution of the present invention is administered by intraocular injection as part of the procedure.
  • the solution of the present invention is administered by irrigation of intraocular tissues during the procedure followed by intraocular injection of a bolus of the solution at the end of the procedure.
  • the solution of the present invention is administered by postoperative injection of a bolus of the solution at the end of the procedure, for example following the identification of the patient being at risk of a postoperative inflammatory condition due to trauma incurred intraoperatively.
  • the solution is administered by intraocular injection preoperatively, intraoperatively and/or postoperatively.
  • the method is used in a procedure selected from vitrectomy, retinal photocoagulation, retinal detachment repair, macular hole repair, retroiris tumor or mass removal, posterior sclerotomy and optic neurotomy, or in connection with the inhibition of inflammatory conditions resulting from intravitreal injections.
  • Postoperative inflammatory conditions inhibited by the methods of the present invention include, for example, toxic anterior-segment syndrome, cystoid macular edema including nonpseudophakic cystoid macular edema and pseudophakic (Irvine-Gass) cystoid macular edema, acute endophthalmitis, posterior capsule opacification, anterior capsule contraction, herpes simplex virus keratitis after cataract surgery, postsurgical hypotony, nylon suture toxicity, long-term corneal endothelial cell loss after cataract surgery, corneal edema, iris chafing, corneo-retinal inflammatory syndrome, scleritis, episcleritis, vitreous wick syndrome, post-operational acute iridocyclitis, uveitis, epiretinal deposits after cataract extraction, reiterative membranous proliferation with giant-cell deposits, toxic vitreitis, posterior synechia, postoperative intraocular fibrin
  • the subject is identified as having an elevated risk of a postoperative inflammatory condition because of a preoperative physiologic condition or characteristic including small pupil diameter (e.g., a dilated preoperative pupil diameter of less than 6 mm), floppy iris syndrome, uveitis, retinal vein occlusion, epiretinal membrane, advanced age (e.g., over 65, elderly or geriatric), diabetes mellitus, diabetic macular edema, diabetic retinopathy, macular degeneration, or systemic hypertension; a preoperative treatment history including previous ocular surgery or pharmacologic treatment with an alpha-1-adrenergic receptor antagonist or latanoprost; surgical trauma including posterior capsule rupture, secondary capsulotomy, iris incarceration, retained lens material, or vitreous loss; and the surgical placement of nylon sutures, iris-fixated intraocular lens or an anterior chamber intraocular lens.
  • small pupil diameter e.g., a dilated preoperative pupil diameter of
  • the subject is identified as having an elevated risk of a postoperative inflammatory condition because of a preoperative physiologic condition or characteristic selected from small pupil diameter (e.g., a dilated preoperative pupil diameter of less than 6 mm), floppy iris syndrome, uveitis, retinal vein occlusion, epiretinal membrane, diabetic macular edema, diabetic retinopathy, macular degeneration, or systemic hypertension; a preoperative treatment history including previous ocular surgery or pharmacologic treatment with an alpha-1-adrenergic receptor antagonist or latanoprost; surgical trauma including posterior capsule rupture, secondary capsulotomy, iris incarceration, retained lens material, or vitreous loss; and the surgical placement of nylon sutures, iris-fixated intraocular lens or an anterior chamber intraocular lens.
  • small pupil diameter e.g., a dilated preoperative pupil diameter of less than 6 mm
  • floppy iris syndrome uveitis, retinal vein
  • the present invention also provides a method for inhibiting a postoperative inflammatory condition following an ophthalmologic surgical procedure by identifying a subject with a physiologic risk of suffering from a postoperative inflammatory condition and administering intraocularly to the subject during an ophthalmologic surgical procedure a solution including a nonsteroidal anti-inflammatory drug (NSAID) and an alpha-1 adrenergic receptor agonist mydriatic agent in an intraocular irrigation carrier, wherein the NSAID and the mydriatic agent are included in the solution in amounts sufficient for the maintenance of intraoperative pupil diameter due to the intraoperative promotion of mydriasis by the mydriatic agent and the intraoperative inhibition of miosis by the NSAID, thereby reducing intraoperative trauma, and for the inhibition of the postoperative inflammatory condition by the intraoperative and postoperative anti-inflammatory effect of the NSAID.
  • NSAID nonsteroidal anti-inflammatory drug
  • an alpha-1 adrenergic receptor agonist mydriatic agent in an intra
  • the present invention provides a method for inhibiting a postoperative inflammatory condition following an ophthalmologic surgical procedure by intraocular administration during an ophthalmologic surgical procedure, to a subject at risk of a postoperative inflammatory condition, a solution including a nonsteroidal anti-inflammatory drug (NSAID) and an alpha-1 adrenergic receptor agonist mydriatic agent in an intraocular irrigation carrier.
  • NSAID nonsteroidal anti-inflammatory drug
  • mydriatic agent in an intraocular irrigation carrier.
  • the NSAID and the mydriatic agent are included in the solution in amounts sufficient to maintain intraoperative pupil diameter by promoting mydriasis and inhibiting miosis, and a sufficient amount of the solution is administered for uptake of an amount of the NSAID in ocular tissues sufficient for inhibition of cyclooxygenases for a period of at least six hours postoperatively, thereby inhibiting the postoperative inflammatory condition.
  • FIGS. 1-3 provide results from the clinical studies of Example 1.
  • FIG. 1 illustrates the mean ( ⁇ SEM) change from baseline in mean pupil diameter (PD) over time to the end of surgery. Pupil diameters were measured at 1-minute intervals from baseline to the end of the procedure and at the end of cortical cleanup from a video recording of the subject's surgery.
  • FIG. 2 illustrates the maximum intraoperative pupil constriction at any time during surgery resulting from the studies.
  • FIG. 3 illustrates the mean ocular pain visual analog scale (VAS) scores during the early postoperative period (full analysis set population).
  • VAS mean ocular pain visual analog scale
  • FIGS. 4-7 provide results from the intracameral dog study of Example 2, and illustrate the mean concentrations of ketorolac in ocular tissues of female dogs at specified time points after the intracameral dosing of phenylephrine 1.0%/ketorolac 0.3% injection in balanced salt solution.
  • FIG. 4 shows ketorolac concentrations in the cornea, lens capsule, iris-ciliary body (ICB), aqueous humor, and anterior sclera.
  • FIG. 5 shows ketorolac concentrations in the bulbar and palpebral conjunctiva.
  • FIG. 6 shows ketorolac concentrations in the vitreous humor, retina, choroid-RPE (peripheral), choroid-RPE (tapetum), and posterior sclera.
  • the present invention provides a method for inhibiting a postoperative inflammatory condition following an ophthalmologic surgical procedure by intraocular administration during an ophthalmologic surgical procedure, to a subject at risk of a postoperative inflammatory condition, a solution including a nonsteroidal anti-inflammatory drug (NSAID) and an alpha-1 adrenergic receptor agonist mydriatic agent in an intraocular irrigation carrier.
  • NSAID nonsteroidal anti-inflammatory drug
  • mydriatic agent are included in the solution in amounts sufficient to maintain intraoperative pupil diameter by promoting mydriasis and inhibiting miosis, thereby reducing the potential for inflammation-inducing trauma to intraocular structures.
  • a sufficient amount of the solution is administered for uptake of an amount of the NSAID in ocular tissues sufficient for inhibition of cyclooxygenases for a period of at least six hours postoperatively, thereby inhibiting or reducing the likelihood or severity of the postoperative inflammatory condition.
  • the present invention may be utilized in a variety of ophthalmologic surgical procedures that are associated with the occurrence of postoperative inflammatory conditions, including anterior segment procedures performed in the anterior chamber or posterior chamber of the eye, and procedures performed in the posterior segment of the eye, such as retinal procedures.
  • the procedure is an intracameral procedure.
  • the ophthalmologic surgical procedure during which the method of the present invention is used is a procedure requiring dilation or mydriasis of the pupil, to provide the surgeon an expanded operative field and visualization of intraocular structures through the dilated pupil.
  • the solution is administered intraocularly by irrigation and/or injection during the procedure to maintain pupil diameter by promoting mydriasis and inhibiting miosis, thereby reducing surgical trauma to the iris and intraocular structures manipulated through the iris.
  • the solution of the present invention may be administered into the anterior segment of the eye, in particular into the anterior chamber or posterior chamber of the eye, or into the posterior segment of the eye.
  • CELR cataract extraction and lens replacement
  • RLE refractive lens exchange
  • vitrectomy retinal photocoagulation
  • retinal detachment repair macular hole repair
  • retroiris tumor or mass removal posterior sclerotomy and optic neurotomy.
  • CELR and RLE may involve femtosecond or scalpel incision, phacoemulsification for lens removal and intraocular lens (IOL) replacement.
  • IOL intraocular lens
  • the present invention may also be used in connection with the inhibition of inflammatory conditions resulting from intravitreal injection, by injecting the solution of the present invention together or concurrently with, or immediately preceding or following, the injection of one or more other therapeutic agents, such as an anti-vascular endothelial growth factor (anti-VEGF) such as ranibizumab.
  • anti-VEGF anti-vascular endothelial growth factor
  • Intraoperative miosis makes the cataract surgical procedure more difficult by shrinking the surgeon's visual field and working space.
  • a small pupil during surgery is associated with increased risk of intraoperative complications, including posterior capsule rupture and vitreous loss.
  • Artzen, D., et al. “Capsule complication during cataract surgery: Case-control study of preoperative and intraoperative risk factors: Swedish Capsule Rupture Study Group report 2 ,” J Cataract Refract Surg 35(10):1688-1693 (2009); Zare, M., et al., “Risk factors for posterior capsule rupture and vitreous loss during phacoemulsification,” J Ophthalmic Vis Res. 4(4):208-212 (2009).
  • Reduced visibility and room for surgical maneuvering may also lead to an increased chance of losing a portion of the lens or the whole lens nucleus into the vitreous cavity (dropping the nucleus) or causing injury to the iris.
  • Intraoperative miosis is frequently associated with intraoperative floppy iris syndrome (IFIS). Eyes with IFIS have loose, billowy iris tissue with increased risk of prolapse and pupil constriction during surgery.
  • IFIS intraoperative floppy iris syndrome
  • Eyes with IFIS have loose, billowy iris tissue with increased risk of prolapse and pupil constriction during surgery.
  • Chang, D. F., Campbell, J. R. “Intraoperative floppy iris syndrome associated with tamsulosin,” J Cataract Refract Surg 31(4):664-673.22 (2005); Chang, D. F., et al., “Prospective multicenter evaluation of cataract surgery in patients taking tamsulosin (Flomax)” Ophthalmology 114(5):957-964 (2007).
  • IFIS al-adrenergic receptor antagonist
  • Flomax an al-adrenergic receptor antagonist
  • Haridas, A, et al. “Intraoperative floppy iris syndrome (IFIS) in patients receiving tamsulosin or doxazosin-a UK-based comparison of incidence and complication rates” Graefes Arch Clin Exp Ophthalmol 251(6):1541-1545 (2013).
  • Tamsulosin is used for the treatment of patients with benign prostatic hyperplasia (noncancerous enlargement of the prostate). Significant intraoperative miosis has been shown to occur in more than 70% of these high-risk patients, even when surgery was performed by highly experienced cataract surgeons. (Chang 2007).
  • Surgical trauma causes intraocular inflammation, even if the procedure is routine and uncomplicated.
  • Lobo, C. “Pseudophakic cystoid macular edema,” Ophthalmologica 227(2):61-67 (2012); Miyake, K., Ibaraki, N., “Prostaglandins and cystoid macular edema” Surv Ophthalmol 2 (47 suppl 1):5203-518 (2002).
  • Inflammation usually begins in the anterior chamber, either at the site of surgical entry or due to direct mechanical stimulation of intraocular structures such as the iris or ciliary body. Early inflammatory pathways are self-perpetuating, which means that inflammation initially grows in intensity and spreads from the anterior chamber to the vitreous and retina. (Lobo 2012); (Miyake 2002).
  • Inflammation is associated with vessel dilation and vascular leakage.
  • retinal vessels leak and the accumulation of excess fluid causes retinal swelling, or edema.
  • Swelling can include the macula, a specialized zone of the central retina that provides sharp detailed vision used in tasks like reading or driving. Retinal swelling that involves the macula is called macular edema.
  • Cystoid macular edema is defined by the presence of anatomically distinct fluid pockets, or cysts. Ismail, R., Sallam, A., “Complications associated with cataract surgery,” Cataract Surgery , Zaidi F.
  • Cystoid macular edema is a primary cause of reduced vision following both cataract and successful vitreoretinal surgery. Loewenstein, A., Zur, D., “Postsurgical Cystoid Macular Edema,” Macular Edema, Dev Ophthalmol ., Coscas, G. (ed.), Basel, Karger 2010:148-159. CME also remains a problem following capsulotomy, penetrating keratoplasty, scleral buckling, filtering procedures, and panretinal photocoagulation.
  • Toxic anterior segment syndrome is an acute postoperative inflammatory reaction in which a noninfectious substance enters the anterior segment and induces toxic damage to the intraocular tissues. Almost all cases occur after uneventful cataract surgery, and, more recently, it has been reported after phakic intraocular lens implantation. This syndrome was previously defined by other names, such as sterile endophthalmitis or postoperative uveitis of unknown cause.
  • TAD toxic endothelial cell destruction
  • Nonsteroidal anti-inflammatory drops have been shown to be a helpful adjunct in several cases of TASS, supporting that TASS is mediated by inflammation.
  • Cystoid macular edema is a painless condition in which swelling or thickening occurs of the central retina (macula) and is usually associated with blurred or distorted central vision. Less common symptoms include metamorphopsia, micropsia, scotomata, and photophobia. CME is a relatively common condition and is frequently associated with various ocular conditions, such as age-related macular degeneration (AMD), uveitis, epiretinal membrane, vitreomacular traction, diabetes, retinal vein occlusion, medicine-related, or following ocular surgery.
  • AMD age-related macular degeneration
  • Irvine-Gass syndrome When CME develops following cataract surgery and its cause is thought to be directly related to the surgery, it is referred to as Irvine-Gass syndrome or pseudophakic CME.
  • Medical therapy of Irvine-Gass syndrome includes NSAIDs, corticosteroids, and carbonic anhydrase inhibitors.
  • NSAIDs NSAIDs
  • corticosteroids corticosteroids
  • carbonic anhydrase inhibitors Recent advances in cataract surgery, such as phacoemulsification, small-incision surgery and advances in foldable intraocular lenses, have resulted in the decrease of physical trauma associated with cataract surgery.
  • the decrease in the physical surgical trauma decreases the release of prostaglandins, which are the main players in postoperative ocular inflammation.
  • postoperative inflammation continues to be a cause of patient discomfort, delayed recovery and, in some cases, suboptimal visual results.
  • NSAIDs are commonly used in the management and prevention of non-infectious ocular inflammation and cystoid macular edema following cataract surgery.
  • Colin, J. “The Role of NSAIDs in the Management of Postoperative Ophthalmic Inflammation,” Drugs 67(9):1291-308 (2007).
  • CME cystoid macular edema
  • numerous other conditions are associated with the clinical appearance of fluid-filled cystoid spaces in the macular region, i.e., nonpseudophakic cystoid macular edema.
  • CME is a final common pathway of many intraocular diseases, usually involving the retinal vasculature. The appearance can differ somewhat, depending on the etiology; however, CME can appear as a nonspecific clinical finding.
  • CME chronic myeloma
  • NSAIDs nonsteroidal anti-inflammatory drugs
  • acetazolamide acetazolamide
  • Nonsteroidal anti-inflammatory drugs may offer equivalent anti-inflammatory efficacy (for both postoperative inflammation and cystoid macular edema) without the typically corticosteroid-associated adverse events. Rowen, S., “Preoperative and Postoperative Medications Used for Cataract Surgery,” Curr Opin Ophthalmol. 10(1):29-35 (1999).
  • the present invention may also suitably be used to inhibit postoperative posterior capsule opacification or anterior capsule contraction.
  • posterior portion of the capsule becomes hazy some time during cataract surgery recovery or even months later, causing posterior capsule opacification.
  • Posterior capsule opacification occurs because lens epithelial cells, remaining after cataract surgery, have grown on the capsule.
  • Knobbe, C. A., M.D. “Cataract Surgery Complications,” http://www.allaboutvision.com/conditions/cataract-complications.htm, accessed Nov. 23, 2014.
  • Sustained-release celecoxib (an NSAID) from incubated acrylic intraocular lenses has been shown to suppress lens epithelial cell growth in an ex vivo model of posterior capsule opacity.
  • the present invention may also be suitably used to inhibit herpes simplex virus keratitis after cataract surgery.
  • Ocular infection with herpes simplex virus (HSV) results in a blinding immunoinflammatory stromal keratitis (SK) lesion.
  • Early preclinical events include polymorphonuclear neutrophil (PMN) infiltration and neovascularization in the corneal stroma.
  • PMN polymorphonuclear neutrophil
  • COX-2 cyclooxygenase 2
  • the induction of COX-2 by HSV infection is a critical event, since inhibition of COX-2 with a selective inhibitor has been shown to reduce corneal angiogenesis and SK severity.
  • ketorolac may prevent post-surgical hypotony due to cyclooxygenase products that are released during cataract surgery and other procedures, indicating further utility for the present invention.
  • a study evaluating inhibition of PGE 2 production by ketorolac, bromfenac and nepafenac in patients undergoing phacoemulsification demonstrated that ketorolac 0.45% achieved the greatest inhibition of PGE 2 compared to nepafenac 0.1% and bromfenac 0.09. Bucci, F.
  • Nylon suture toxicity may also result in postoperative inflammation and be suitably inhibited by use of the present invention.
  • a cluster of symptoms and signs that developed in 10 of 105 consecutive patients (9.5%) who underwent uncomplicated planned extracapsular cataract extraction (ECCE) with posterior chamber intraocular lens (PC IOL) implants has been reported as appearing to be related to wound closure.
  • These signs and symptoms included foreign body sensation, conjunctival injection and infiltrates localized to the scleral wound, and scleral excavation underlying the running 10-0 nylon suture possibly resulting from localized scleral edema.
  • the time of clinical presentation ranged from 1 to 6 weeks.
  • Conjunctival stains demonstrated eosinophils and polymorphonuclear leukocytes in some cases.
  • Cataract surgery can in some cases result in long-term corneal endothelial cell loss, while vitrectomy may result in corneal edema, both conditions that may be inhibited by the present invention.
  • Three-day and 1-day dosing of ketorolac has been shown to reduce surgical time, phacoemulsification time and energy, and endothelial cell loss and improved visual acuity in the immediate postoperative period compared with 1-hour predosing or use of a placebo.
  • Donnenfeld, E. D., et al. “Preoperative Ketorolac Tromethamine 0.4% in Phacoemulsification Outcomes: Pharmacokinetic-response Curve,” J Cataract Refract Surg.
  • Ketorolac tromethamine 0.5% ophthalmic solution has been shown to be effective and well-tolerated in controlling postoperative inflammation. Simone, J. N., “Comparison of the Efficacy and Safety of Ketorolac Tromethamine 0.5% and Prednisolone Acetate 1% after Cataract Surgery,” J Cataract Refract Surg. 25(5):699-704 (1999).
  • Intraocular lens implantation may be associated with a corneo-retinal inflammatory syndrome that leads to corneal decompensation and cystoid macular edema.
  • the inflammatory aspects often do not appear striking but manifest as mild ciliary flush, mild flare, moderate cells in the anterior chamber, and moderate vitritis.
  • the cornea will decompensate in the presence of endothelial cell counts which are sufficient to maintain corneal clarity in the non-inflamed eye.
  • Metal-looped lenses and poorly polished lenses cause iris chafing and capillary leakage, which increase the severity of this syndrome. It is postulated that intraocular surgery initiates an inflammatory response that is augmented by certain components of intraocular lenses.
  • the mediation for this increased inflammatory response may be inhibited by both steroidal and non-steroidal anti-inflammatory agents.
  • white blood cells and their products such as lysosomal enzymes, may be sufficient to perpetuate the inflammatory response and cause damage to abnormal and normal cells.
  • protein and its immune components, as well as complement may be involved in this syndrome. Obstbaum, S. A., et al., “Cystoid Macular Oedema and Ocular Inflammation. The Corneo-Retinal Inflammatory Syndrome,” Trans Ophthalmol Soc U K 99(1):187-91 (1979).
  • Postsurgical scleritis and episcleritis may also be inhibited by use of the present invention.
  • a number of cases of necrotic sclerokeratitis following eye surgery have been reported in recently published literature. The condition was presumably triggered by surgical inflammation and caused by localized occlusive vasculitis: in one case deposits of immune complexes in vessel walls were demonstrated.
  • Clinical examination shows disappearance of vessels in affected sclera, together with tissue necrosis.
  • Gregersen, E., et al. “Necrotizing Sclerokeratitis Following Cataract Extraction,” Klin Monbl Augenheilkd. 193(6):642-4 (1988).
  • Vitreous wick syndrome occurs after eye surgery and consists of microscopic wound breakdown, followed by a vitreous prolapse that develops into a vitreous wick, and may also be suitably inhibited by practice of the present invention. Vitreous wick syndrome develops in the setting of trauma, either iatrogenic or noniatrogenic. Vitreous wick syndrome of iatrogenic origin usually follows anterior-segment surgery, though it may also follow subtenon injection and muscle surgery. Corneal wound healing has been documented to be slower on the endothelial side (inner layers). Poor suturing technique is implicated as a major factor for wound breakdown.
  • Tightly compressed corneal wound edges may demonstrate puckering and also may lead to enlargement of suture tracts, promoting tissue necrosis within the suture loop.
  • anterior aqueous fluid may egress; vitreous incarceration may also occur, producing the vitreous wick.
  • complete sloughing of strangulated tissue within the suture loop may occur.
  • Post-operational acute iridocyclitis, or post-surgical inflammation of the iris and ciliary body also provides a treatment opportunity for the present invention.
  • Evaluation of the adjunctive use of nonsteroidal anti-inflammatory drugs for the treatment of chronic iridocyclitis in 14 patients has been reported, eight of whom had juvenile rheumatoid arthritis and six with idiopathic iridocyclitis.
  • the activity of the iridocyclitis improved with the addition of NSAIDs to their treatment regimens, permitting reduction in the dose of corticosteroid drugs.
  • the present invention may additionally be used to inhibit inflammation due to epiretinal deposits after cataract extraction.
  • inflammation was found to be limited to the posterior segment, and investigative work-up for infective causes was negative.
  • Reiterative membranous proliferation with giant-cell deposits may follow some cases of cataract surgery.
  • One report addresses the outcomes of a 72-year-old Japanese woman and a 67-year-old Japanese man who underwent AcrySof IOL (SA60AT) implantation in their eyes (both eyes in the first case and the left eye in the second case) for the treatment of cataract and vitreous opacity with uveitis.
  • SA60AT AcrySof IOL
  • the number of giant-cell deposits on the posterior surface of the posterior capsule was gradually increased with the development of posterior capsular opacification in 5 and 9 months, respectively, and neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser capsulotomy was required.
  • Nd:YAG neodymium-doped yttrium-aluminum-garnet
  • a report of 11 cases of intraocular inflammation after intravitreal injection indicates another suitable use of the present invention. Only one of these cases involved infectious endophthalmitis with retinal abscess, with all others involving toxic vitreitis. Seven eyes exhibited hypopyon and five disseminated retinal hemorrhages. The toxic reaction occurred within 48 hours after injection, whereas in the endophthalmitis case, it occurred after 72 hours. The cause of this reaction was believed by the reporting authors to be the particular syringe brand used. After changing to another syringe brand, no further cases of toxic vitreitis occurred during the next 6 months. Ness, T., et al., “Toxic Vitreitis Outbreak After Intravitreal Injection,” Retina. 30 (2):332-8 (2010).
  • a synechia is an eye condition where the iris adheres to either the cornea (i.e., anterior synechia) or lens (i.e., posterior synechia), and instances of this condition following surgical procedures may be inhibited by the present invention.
  • Synechiae can be caused by ocular trauma, ulceris or iridocyclitis and may lead to certain types of glaucoma.
  • Topical corticosteroids have conventionally been used to subdue the inflammation.
  • the present invention may also be used to inhibit postoperative intraocular fibrin formation.
  • the anti-inflammatory effect of 0.1% diclofenac sodium on anterior inflammation after cataract surgery has been reported. Fibrin precipitation after surgery in patients without systemic or ocular disease was markedly less when diclofenac sodium ophthalmic solution was used in combination with topical corticosteroids. There was also a reduction in fibrin precipitation in other patients, especially in those with diabetes mellitus, primary angle-closure glaucoma, and exfoliation syndrome. Matsuo, K., et al., “Clinical Efficacy of Diclofenac Sodium on Postsurgical Inflammation After Intraocular Lens Implantation,” Refract Surg. 21 (3):309-12 (1995).
  • the present invention may be useful for treating choroidal neovascularization and other complications following surgical treatment for macular holes.
  • posterior segment complications were noted in 39 eyes (41%).
  • the incidence of retinal pigment epithelium alteration and retinal detachment were 33% and 11%, respectively.
  • One case of retinal detachment due to a giant retinal tear resulted in a visual acuity of light perception.
  • Other complications included a reopening of the macular hole in two eyes (2%), cystoid macular edema in one eye (1%), a choroidal neovascular membrane in one eye (1%) and endophthalmitis in one eye (1%). Banker, A.
  • Choroidal effusion which is an abnormal accumulation of fluid in the suprachoroidal space, is a common complication of glaucoma surgery and may suitably be inhibited by the practice of the present invention. Choroidal effusion may also arise from other intraocular surgical procedures as well as a number of conditions, including inflammatory and infectious diseases, trauma, neoplasms, drug reactions, and venous congestion. Idiopathic causes fall under the umbrella of uveal effusion syndrome, a rare condition usually considered a diagnosis of exclusion. Reddy, A.
  • Hypopyon is seen as yellowish exudate in the lower part of the anterior chamber of the eye and is formed of inflammatory cells. It is a leukocytic exudate and is a sign of inflammation of the anterior uvea and iris, i.e., ulceris, which is a form of anterior uveitis. Hypopyon has been reported in a patient with rheumatoid arthritis undergoing phacoemulsification. This 70-year-old woman was on a maintenance dose of systemic methylprednisolone at the time of uneventful phacoemulsification in the left eye.
  • the present invention also provides a method for inhibiting a postoperative inflammatory condition following an ophthalmologic surgical procedure by identifying a subject with a physiologic risk of suffering from a postoperative inflammatory condition and administering intraocularly to the subject during an ophthalmologic surgical procedure a solution including a nonsteroidal anti-inflammatory drug (NSAID) and an alpha-1 adrenergic receptor agonist mydriatic agent in an intraocular irrigation carrier, wherein the NSAID and the mydriatic agent are included in the solution in amounts sufficient for the inhibition of the postoperative inflammatory condition.
  • NSAID nonsteroidal anti-inflammatory drug
  • mydriatic agent alpha-1 adrenergic receptor agonist mydriatic agent
  • Systemic diseases, intraoperative complications and preexisting ocular conditions are risk factors that influence the development of CME.
  • Systemic risk factors for postsurgical CME include diabetes mellitus, which promotes the development of CME even in the absence of diabetic retinopathy.
  • Schmier J., et al. “Evaluation of costs for cystoid macular edema refractory to topical medications,” Ophthalmology 104:2003-2008 (1997).
  • Systemic hypertension apparently increases the incidence of postsurgical CME. Flach, A., “The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery,” Trans Am Ophthalmol Soc 96:557-634 (1998).
  • Systemic hypertension is also a risk factor for retinal vein occlusion, which itself increases CME. (Loewenstein 2010).
  • Certain preexisting conditions also increase the risk of postsurgical CME. These conditions may compromise the integrity of the blood-retinal barrier and boost inflammatory activity. These include uveitis, in which CME is the most important cause for poor visual outcomes following cataract surgery. (Loewenstein 2010). As noted above, preoperative diabetic retinopathy considerably increases the risk of onset and persistence of CME (Iliff, W., “Aphakic cystoid macular edema and the operating microscope: is there a connection?” Trans Am Ophthalmol Soc 83:476-500 (1985)), while a history of retinal vein occlusion and epiretinal membrane (ERM) also predict development of CME.
  • a subject to be treated with the NSAID and an alpha-1 adrenergic receptor agonist solution of the invention is identified as having an elevated risk of a postoperative inflammatory condition because of a preoperative physiologic condition or characteristic including small pupil diameter (e.g., a dilated preoperative pupil diameter of less than 6 mm), floppy iris syndrome, uveitis, retinal vein occlusion, epiretinal membrane, advanced age (e.g., over 65, elderly or geriatric), diabetes mellitus, diabetic macular edema, diabetic retinopathy, macular degeneration, or systemic hypertension; a preoperative treatment history including previous ocular surgery or pharmacologic treatment with an al-adrenergic receptor antagonist or latanoprost; surgical trauma including posterior capsule rupture, secondary capsulotomy, iris incarceration, retained lens material, or vitreous loss; and the surgical placement of nylon sutures, iris-fixated
  • “elevated risk” of a postoperative inflammatory condition refers to a subject whose risk of experiencing a postoperative inflammatory condition following an ophthalmologic procedure is greater than the mean incidence rate of the same postoperative inflammatory condition in healthy subjects who do not have any predisposing risk characteristics that are undergoing the same procedure.
  • Subjects at elevated risk of postoperative inflammation may be identified by the surgeon in advance of surgery as having an elevated risk of postoperative inflammation based on the patient's preoperative physiologic condition or characteristic or preoperative treatment history, or the planned placement of sutures or intraocular devices that are associated with an enhanced incidence of postoperative inflammation. Once identified, the surgeon may administer the solution of the present invention during the operative procedure to preemptively decrease or reduce the incidence or severity of postoperative inflammation.
  • surgeon may prophylactically administer the solution of the present invention during the operative procedure to address an enhanced risk of postoperative inflammation that may be identified during the procedure due to the nature of surgical trauma, e.g., posterior capsule rupture, secondary capsulotomy, iris incarceration, retained lens material, or vitreous loss, or unplanned use of sutures or devices that are associated with an enhanced incidence of postoperative inflammation.
  • surgical trauma e.g., posterior capsule rupture, secondary capsulotomy, iris incarceration, retained lens material, or vitreous loss, or unplanned use of sutures or devices that are associated with an enhanced incidence of postoperative inflammation.
  • the method of the present invention provides for the intraoperative delivery of a combination of an NSAID and an alpha-1 adrenergic receptor agonist mydriatic agent.
  • the NSAID is ketorolac and the alpha-1 adrenergic receptor agonist mydriatic agent is phenylephrine.
  • Suitable non-steroidal anti-inflammatory drugs for use in the present invention include flurbiprofen, suprofen, diclofenac, ketoprofen, ketorolac, indomethacin, nepafenac and bromfenac.
  • a preferred NSAID is ketorolac.
  • “ketorolac” means ketorolac in a salt form, such as ketorolac tromethamine [(+/ ⁇ )-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid:2-amino-2(hydroxymethyl)-1,3-propanediol (1:1)].
  • Ketorolac in one formulation of the present invention is included as the ketorolac tromethamine salt [(+/ ⁇ )-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid:2-amino-2(hydroxymethyl)-1,3-propanediol (1:1)].
  • Ketorolac is a member of the pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs.
  • Ketorolac HCL is a racemic mixture of the R-(+) and S-( ⁇ ) enantiomers that may exist in three crystal forms, all of which are equally soluble in water.
  • Ketorolac is a nonsteroidal anti-inflammatory that inhibits both cyclooxygenase enzymes (COX-1 and COX-2), and when used in accordance with the present invention results in a decrease in tissue concentrations of prostaglandins to reduce pain due to surgical trauma.
  • Ketorolac by inhibiting prostaglandin synthesis secondary to ocular surgical insult or direct mechanical stimulation of the iris, also prevents surgically induced miosis when used in accordance with the present invention.
  • Suitable alpha-1 adrenergic receptor agonists for use as mydriatic agents in the present invention include, for example, phenylephrine, epinephrine, oxymetazoline and naphazoline.
  • a preferred alpha-1 adrenergic receptor agonist is phenylephrine.
  • phenylephrine means phenylephrine in a salt form, such as phenylephrine HCL [( ⁇ )-m-Hydroxy-a-[(methyl amino)methyl]benzyl alcohol hydrochloride].
  • Phenylephrine is an alpha-1 adrenergic receptor agonist and, in the eye, acts as a mydriatic agent by contracting the radial muscle of the iris.
  • the NSAID and alpha-1 adrenergic receptor agonist solution is administered intraocularly by irrigation and/or injection during the procedure to maintain pupil diameter by promoting mydriasis and inhibiting miosis, thereby reducing surgical trauma to the iris and intraocular structures manipulated through the iris.
  • a mydriatic agent e.g., phenylephrine
  • an anti-miotic agent e.g., ketorolac
  • the in vivo study using paracentesis in a rabbit model of surgical trauma described above demonstrates that, following ocular surgical trauma, prostaglandin levels remain elevated for a period of up to seven hours.
  • the in vivo study in dogs to determine the concentrations of ketorolac in the retina and other ocular tissues following the intracameral administration of a phenylephrine and ketorolac solution, described in Example 2 below demonstrates that the intraoperative uptake of ketorolac by retina and other ocular tissues is surprisingly at levels sufficient to inhibit COX-1 and COX-2 levels by at least 90% in ocular tissues for at least 8 hours following drug administration, and by at least 85% in ocular tissues for at least 10 hours following drug administration.
  • the present invention inhibits inflammation during the surgical procedure, both by reducing trauma through complimentary mydriatic and anti-miotic effects and by preemptively inhibiting prostaglandin release, and continues to inhibit inflammation during the period when postsurgical cyclooxygenase levels are most elevated.
  • the NSAID and alpha-1 adrenergic receptor agonist are contained in an aqueous solvent as a carrier to provide a drug composition or solution.
  • the aqueous carrier is suitably water for injection (WFI), which is a sterile, solute-free preparation of distilled water.
  • WFI water for injection
  • other aqueous carriers that are not harmful to intraocular tissues and which would not adversely affect the stability of the formulation may be used, such as deionized water, or, after first evaluating for potential impact on stability, saline or a balanced salt solution such as that described below.
  • the solution of the NSAID and alpha-1 adrenergic receptor agonist of the present invention is suitably adjusted to a pH from 5.8 to 6.8, and preferably to about 6.3.
  • Sodium hydroxide and hydrochloric acid may be added as required to adjust the formulation to this pH.
  • the desired pH is suitably maintained by use of a buffering system.
  • a buffering system is a citrate buffer, including citric acid monohydrate and sodium citrate dehydrate
  • a sodium phosphate buffer including dibasic sodium phosphate and monobasic sodium phosphate.
  • Either buffer system may be used at an appropriate concentration in the range of 10 mM to 100 mM, and suitably may be 20 mM.
  • sodium citrate is a preferred buffer for use in a preservative- and antioxidant-free formulation.
  • the citric acid in the citrate buffer which has the ability to chelate divalent cations and can thus also prevent oxidation, provides an antioxidant effect as well as a buffering effect.
  • antioxidant free precludes the use of other antioxidants but does not preclude the use of a buffering agent, such as citric acid, that is included as part of the buffering system.
  • the NSAID and alpha-1 adrenergic receptor agonist solution of the present invention is suitably diluted into an intraocular irrigation solution by injection into a bag, bottle or other container of an intraocular irrigation solution prior to administration by intraocular irrigation or injection.
  • Suitable intraocular irrigation solutions include saline, lactated Ringer's, balanced salt solution or any other irrigation solution that is compatible with the aqueous formulation and not harmful to ocular tissues.
  • One suitable intraocular irrigation carrier includes one or more, and preferably all, of the following adjuvants: sufficient electrolytes to provide a physiological balanced salt solution; a cellular energy source; a buffering agent; and a free-radical scavenger.
  • BSS balanced salt solution
  • electrolytes of from 50 to 500 millimolar sodium ions, from 0.1 to 50 millimolar potassium ions, from 0.1 to 5 millimolar calcium ions, from 0.1 to 5 millimolar magnesium ions, from 50 to 500 millimolar chloride ions, and from 0.1 to 10 millimolar phosphate bicarbonate as a buffer at a concentration of from 10 to 50 millimolar; a cellular energy source selected from dextrose and glucose, at a concentration of from 1 to 25 millimolar; and glutathione as a free-radical scavenger (i.e., antioxidant) at a concentration of from 0.05 to 5 millimolar.
  • One example of a suitable method of diluting and administering the preferred phenylephrine and ketorolac composition of the present invention utilizes the formulation of the present invention described in Table 1 below.
  • An aliquot of 4.5 mL of this solution, including 4.0 mL as the intended quantity for single use and 0.5 mL of overfill, is contained within a sterile closed single-use vial and is intended for admixture with irrigation solution for administration during intraocular surgery.
  • a sterile liquid pharmaceutical formulation for irrigation may be provided in which the phenylephrine and ketorolac are already admixed within an intraocular irrigation carrier, such that it has been diluted to the concentration of each active pharmaceutical ingredient desired for local delivery to intraocular tissues during surgery, and contained within a sterile bag, bottle or other irrigation container.
  • a formulation for irrigation may include phenylephrine at a concentration of from 30 to 720 ⁇ M and ketorolac at a concentration of from 10 to 270 or preferably may include the phenylephrine at a concentration of from 90 to 720 ⁇ M and the ketorolac at a concentration of from 44 to 134 ⁇ M.
  • an exemplary stable, liquid pharmaceutical formulation of the present invention includes phenylephrine and ketorolac in a buffered aqueous carrier.
  • Suitable concentrations of phenylephrine in the combination drug compositions of the present invention range from 10 mM to 500 mM, and preferably from 45 mM to 112 mM.
  • Suitable concentrations of ketorolac in the combination drug compositions of the present invention range from 2 mM to 75 mM, and preferably from 8.5 mM to 24 mM.
  • a buffer system such as a sodium citrate buffer system, is suitably included at a concentration of from 10 to 100 mM, and preferably at about 20 mM.
  • An exemplary formulation for use in accordance with the present invention is set forth in Table 1 below. Sodium hydroxide and/or hydrochloric acid may be added when preparing the formulation if necessary to adjust the pH to about 6.3.
  • the amounts of pharmaceutically active ingredients included in the formulation can be expressed in molar ratios.
  • the molar ratio of phenylephrine to ketorolac may range from 1:1 to 13:1, and more suitably may range from 3:1 to 10:1.
  • An exemplary molar ratio of phenylephrine and ketorolac as represented in Table 1 above is 5.4:1 of phenylephrine to ketorolac.
  • the dosing concentration of phenylephrine may be from 3 to 7,200 more suitably from 30 to 720 more preferably from 90 to 720 still more preferably from 240 to 720 and most preferably about 483 ⁇ M.
  • the dosing concentration of ketorolac may be from 3 to 900 more suitably from 10 to 270 more preferably from 44 to 134 still more preferably from 30 to 90 and most preferably about 90 ⁇ M.
  • This example describes two Phase 3 clinical studies performed to evaluate the efficacy and safety of phenylephrine 1% and ketorolac 0.3% injection formulated as described in Table 1 above when used for the maintenance of mydriasis during, and prevention of postoperative pain following, cataract surgery and intraocular lens (IOL) replacement.
  • OMS302 483 ⁇ M phenylephrine and 89 ⁇ M ketorolac formulated in 20 mM sodium citrate buffer) or placebo (20 mM sodium citrate buffer
  • BSS balanced salt solution
  • Postoperative evaluations were conducted for up to 14 days (Study 1) or 90 days (Study 2); integrated safety analyses were limited to data collected up to 14 days post-surgery. All subjects (OMS302-treated and placebo-treated) in the studies received standard-of-care preoperative topical mydriatic and anesthetic agents.
  • VAS visual analog scale
  • Post-hoc secondary analyses included categorization of subjects' intraoperative pupil constriction and analgesic use on day of surgery.
  • the mean AUC pupil diameter change from baseline during surgery was calculated as follows: 1) the trapezoidal rule was used to calculate the AUC of the pupil diameter from surgical baseline to wound closure, 2) the result was divided by time of the last pupil diameter value to obtain the mean AUC, and 3) the baseline pupil diameter was subtracted from the mean AUC.
  • the AUC of ocular pain VAS during the first 10-12 postoperative hours was also calculated using the trapezoidal rule with the mean AUC defined as the AUC divided by the number of hours from the first VAS score to the last VAS score within this time frame.
  • a generalized Cochran-Mantel-Haenzel (CMH) test stratified by randomization strata was used to compare the two treatment arms for the two studies combined (LaVange, et al. 2005).
  • OMS302 was superior to placebo in maintaining mydriasis during cataract surgery or IOL replacement procedures.
  • SE standard error
  • Results of secondary efficacy analyses evaluating incidence of subjects with pupil diameter ⁇ 6 mm at completion of cortical clean up and at any time during surgery also favored OMS302 treatment (Table 2).
  • the proportions of subjects with pupil diameter ⁇ 6 mm at the time of cortical clean-up completion, pupil diameter ⁇ 6 mm at any time during surgery, and degree of intraoperative pupillary constriction of ⁇ 2.5 mm were all significantly lower among OMS302-treated subjects than placebo-treated subjects (p ⁇ 0.0001 for each endpoint).
  • OMS302-treated subjects than placebo subjects experienced intraoperative pupil constriction greater than 1 mm ( FIG. 2 ).
  • OMS302 Treatment with OMS302 was associated with a significant reduction in early postoperative ocular pain compared to placebo.
  • Mean VAS scores were lower among subjects treated with OMS302 at each postoperative time point ( FIG. 3 ).
  • TEAE treatment-emergent adverse event
  • the most frequently-reported TEAE consisted of eye pain (reported by 35.1% of subjects overall), eye inflammation (15.5%), anterior chamber inflammation (8.7%), headache (7.9%), intraocular pressure increased (4.1%), posterior capsule opacification (4.1%), ocular discomfort (4.1%), photophobia (4.0%), corneal edema (2.8%), vision blurred (2.7%), conjunctival hyperemia (2.6%), and foreign body sensation in the eyes (2.2%).
  • Increased intraocular pressure was observed for several subjects in both treatment groups following surgery. By Day 2, increases compared to baseline were less notable; however, the abnormality persisted in some subjects through the end of the study. No notable TEAEs were reported in these subjects and no differences in the proportions of subjects with increased intraocular pressure were observed between the two treatment groups on each evaluation day. In addition, no differences between treatment groups were observed for any other serial assessments of safety (i.e., vital signs or ophthalmological exams).
  • OMS302 was superior to placebo for the maintenance of mydriasis during, and reduction of ocular pain following, IOL replacement.
  • the mean area-under-the-curve (AUC) change from baseline in pupil diameter was 0.08 mm for OMS302 compared to ⁇ 0.50 mm for placebo (p ⁇ 0.0001).
  • This example describes the results of an in vivo study in dogs to determine the concentrations of ketorolac in the retina and other ocular tissues following the intracameral administration of phenylephrine 1% and ketorolac 0.3% injection formulated as described in Table 1 (OMS302) during IOL replacement in dogs.
  • IOL replacement by phacoemulsification was performed on 20 female beagles.
  • OMS302 was administered in BSS solution via irrigation and intracameral injection immediately post-procedure.
  • the target dose level of ketorolac was 5.71 mg/eye
  • the target dose volume of OMS302 diluted in BSS solution was 250 mL per eye.
  • Four animals per time point were sacrificed at 0, 2, 6, 8, and 10 hours post-procedure.
  • Samples of blood and aqueous humor were collected. Enucleated eyes were frozen and dissected for collection of retina, retinal pigmented epithelium-choroid, cornea, iris-ciliary body, vitreous humor, sclera, and lens capsule.
  • LCMS liquid chromatography/mass spectrometry
  • FIGS. 4-6 illustrate the mean concentrations of ketorolac at specified time points after the intracameral doses of OMS302, with FIG. 4 showing ketorolac concentrations in the cornea, lens capsule, iris-ciliary body (ICB), aqueous humor, and anterior sclera; FIG. 5 showing ketorolac concentrations in the bulbar and palpebral conjunctiva; and FIG. 6 showing the ketorolac concentrations in vitreous humor, retina, choroid-RPE (peripheral), choroid-RPE (tapetum), and posterior sclera.
  • FIG. 4 shows ketorolac concentrations in the cornea, lens capsule, iris-ciliary body (ICB), aqueous humor, and anterior sclera
  • FIG. 5 showing ketorolac concentrations in the bulbar and palpebral conjunctiva
  • FIG. 6 showing the ketorolac concentrations in vitreous humor, retina, choroid-RPE (peripheral), cho
  • the retinal half-life was ⁇ 3.8 hours.
  • retinal tissue concentrations were 97.74% (with a standard deviation of 0.36%) for COX-1 and 87.82 (with a standard deviation of 1.75%) for COX-2.
  • OMS302 during IOL replacement surgery resulted in the uptake of ketorolac by retina and other ocular tissues at levels sufficient to inhibit COX-1 and COX-2 levels in intraocular tissues by greater than 90% for at least 8 hours, and by greater than 85% for at least 10 hours, following drug administration in the intracameral irrigation solution, which duration of action was unexpected.
  • Systemic exposure was low and transient.
  • This example describes the results of a clinical study to determine postoperative intracameral concentrations of ketorolac in subjects receiving topical ketorolac prior to cataract surgery.
  • ketorolac Thirteen of 14 subjects used four doses of ketorolac the day prior to surgery, and one subject used three doses the day prior to surgery. All 14 subjects received topical ketorolac in the surgery center on the day of surgery. Aqueous humor samples were inadvertently not collected from two subjects. The preoperative ketorolac concentrations for the 12 subjects on whom samples were collected ranged from 4.9 to 369 ng/mL. The end-of-procedure samples ranged from ⁇ 1.0 (the lower limits of quantification, or LLOQ) to 6.32 ng/mL, with eight of the 12 subjects having ketorolac levels below the LLOQ.
  • LLOQ the lower limits of quantification
  • At-home compliance with topical ketorolac was generally good, with 92.9% of subjects using topical ketorolac as directed. Following CELR, levels of ketorolac in the aqueous humor at the end of the surgical procedure were low, likely due to irrigation wash-out, as 66.7% of subjects had an undetectable concentration of ketorolac.
US14/953,806 2014-12-01 2015-11-30 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions Abandoned US20160279099A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US14/953,806 US20160279099A1 (en) 2014-12-01 2015-11-30 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
US15/836,772 US20180280350A1 (en) 2014-12-01 2017-12-08 Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
US16/276,337 US11234965B2 (en) 2014-12-01 2019-02-14 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
US17/554,842 US20220175727A1 (en) 2014-12-01 2021-12-17 Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086133P 2014-12-01 2014-12-01
US14/953,806 US20160279099A1 (en) 2014-12-01 2015-11-30 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/836,772 Continuation US20180280350A1 (en) 2014-12-01 2017-12-08 Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions

Publications (1)

Publication Number Publication Date
US20160279099A1 true US20160279099A1 (en) 2016-09-29

Family

ID=56092655

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/953,806 Abandoned US20160279099A1 (en) 2014-12-01 2015-11-30 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
US15/836,772 Abandoned US20180280350A1 (en) 2014-12-01 2017-12-08 Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
US16/276,337 Active US11234965B2 (en) 2014-12-01 2019-02-14 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
US17/554,842 Pending US20220175727A1 (en) 2014-12-01 2021-12-17 Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/836,772 Abandoned US20180280350A1 (en) 2014-12-01 2017-12-08 Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
US16/276,337 Active US11234965B2 (en) 2014-12-01 2019-02-14 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
US17/554,842 Pending US20220175727A1 (en) 2014-12-01 2021-12-17 Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions

Country Status (16)

Country Link
US (4) US20160279099A1 (zh)
EP (2) EP3949961A1 (zh)
JP (3) JP2018500295A (zh)
KR (2) KR20170088875A (zh)
CN (2) CN106999472A (zh)
AR (2) AR102691A1 (zh)
AU (1) AU2015355289B2 (zh)
BR (1) BR112017011648A8 (zh)
CA (1) CA2967687A1 (zh)
CL (1) CL2017001303A1 (zh)
HK (1) HK1244705A1 (zh)
IL (1) IL252559A0 (zh)
MX (2) MX2017006829A (zh)
RU (1) RU2750296C2 (zh)
TW (2) TWI809304B (zh)
WO (1) WO2016089739A2 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855246B2 (en) 2012-10-24 2018-01-02 Omeros Corporation Stable preservative-free mydriatic and anti-inflammatory solutions for injection
WO2018089467A1 (en) * 2016-11-09 2018-05-17 Beth Israel Deaconess Medical Center, Inc. Methods for reducing recurrence of tumors
US11234965B2 (en) 2014-12-01 2022-02-01 Omeros Corporation Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550022A (en) 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
JPS58126810A (ja) 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
WO1987007141A1 (en) 1986-05-23 1987-12-03 New England Medical Center Hospitals, Inc. Method for treating glaucoma
US5212196A (en) 1986-10-21 1993-05-18 Alcon Laboratories, Inc. Control of post-surgical intraocular pressure using clonidine derivatives
US4938970A (en) 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US5110493A (en) 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US4876250A (en) 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5051443A (en) 1988-10-12 1991-09-24 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
US5036046A (en) 1988-10-12 1991-07-30 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
US5371078A (en) 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5116868A (en) 1989-05-03 1992-05-26 The Johns Hopkins University Effective ophthalmic irrigation solution
WO1991002527A1 (en) 1989-08-21 1991-03-07 Beth Israel Hospital Association Method and composition for the treatment of cutaneous, ocular, and mucosal hypersensitivity, inflammation, and hyperproliferative conditions using topical preparations of serotonin antagonists
US5679650A (en) 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
EP0502143B1 (en) 1990-09-07 1995-11-08 Universidad De Alicante Composition for treating ocular pain
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
IT1252692B (it) 1991-11-27 1995-06-23 Zambon Spa Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
WO1994008602A1 (en) 1992-10-21 1994-04-28 Alcon Laboratories, Inc. Composition for irrigating intraocular tissues and maintaining mydriasis during intraocular surgery
US6117907A (en) 1993-04-14 2000-09-12 Sher; Neal A. Topical treatment of ocular pain after corneal surgery
WO1995009004A1 (en) 1993-09-29 1995-04-06 Alcon Laboratories, Inc. Compositions containing growth factors and antiplastic agents
WO1995009003A1 (en) 1993-09-29 1995-04-06 Alcon Laboratories, Inc. Compositions containing growth factors and antimetabolites
US5624893A (en) 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
EP0734248A1 (en) 1993-12-17 1996-10-02 Alcon Laboratories, Inc. Improved intraocular irrigating solution containing non-steroidal antiinflammatory agent
US6350781B1 (en) 1994-01-14 2002-02-26 Lee Shahinia, Jr. Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine
WO1995034298A1 (en) 1994-06-10 1995-12-21 Telor Ophthalmic Pharmaceuticals, Inc. Inhibition of intraoperative miosis/production of mydriasis by local anesthetics
US5523316A (en) 1994-06-23 1996-06-04 Alcon Laboratories, Inc. Intraocular irrigating solution containing agent for controlling IOP
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
WO2000023062A2 (en) 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
KR100517210B1 (ko) 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
CA2206119C (en) 1994-12-12 2008-05-13 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US5972326A (en) 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5767105A (en) 1995-05-03 1998-06-16 Peyman; Gholam A. Ocular solution
US5798356A (en) 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US6280745B1 (en) 1997-12-23 2001-08-28 Alliance Pharmaceutical Corp. Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
GB9704352D0 (en) 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
WO1998043619A2 (en) 1997-04-02 1998-10-08 The Regents Of The University Of California Method of local anesthesia
US5811446A (en) 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6495598B1 (en) 1997-04-22 2002-12-17 Ophtecs Corporation Perfusate preparation for ophthalmic operation
EP0903151A1 (en) 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
AU772807B2 (en) 1998-07-01 2004-05-06 Warner-Lambert Company Llc (-)-pseudoephedrine as a sympathomimetic drug
JP2002520355A (ja) 1998-07-14 2002-07-09 アルコン ラボラトリーズ， インコーポレイテッド 非アレルギー性眼炎症障害を処置および眼新生血管形成を予防する医薬製造のための、１１−（３−ジメチルアミノプロピリデン）−６，１１−ジヒドロジベンズ［ｂ，ｅ］オキセピン−２−酢酸の使用
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
EP1261334A1 (en) 1998-10-20 2002-12-04 Omeros Corporation Irrigation solution containing mapk inhibitors and their use for treating pain and inflammation
US20030087962A1 (en) 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
DE69924536T2 (de) 1998-10-20 2006-02-16 Omeros Corp., Seattle Spülende lösung und methoden zur hemmung von schmerzen und entzündungen
US7973068B2 (en) 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
AU1214800A (en) 1998-10-21 2000-05-08 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
DE69937070D1 (de) 1998-11-05 2007-10-18 Omeros Corp Spüllösung und verfahren zur schmerzlinderung und entzündungshemmung
US6433007B1 (en) 1998-12-17 2002-08-13 Alcon Manufacturing, Ltd. Methods for the prevention and treatment of post-surgical complications
MXPA01008729A (es) 1999-03-02 2003-06-24 Vitreo Retinal Technologies In Agentes para administracion intravitrea para tratar o prevenir desordenes del ojo.
CN1353573A (zh) 1999-05-14 2002-06-12 加利福尼亚大学董事会 对炎症介导感染的抗炎症治疗
CA2388828A1 (en) 1999-10-22 2001-06-14 Transdermatech, Inc. Topical anesthetic formulation
US6218428B1 (en) 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
KR20030060771A (ko) 2000-04-28 2003-07-16 메모리얼 슬로안-케터링 캔서 센터 국소용 마취제/아편양약물 제제 및 이들의 용도
JP2004503601A (ja) 2000-07-13 2004-02-05 ファルマシア・コーポレーション 眼のｃｏｘ−２媒介疾患の処置及び予防におけるｃｏｘ−２阻害剤の使用法
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
JP2004503593A (ja) 2000-07-14 2004-02-05 アラーガン、インコーポレイテッド 増大した溶解度を持つ治療活性成分を含む組成物
AR035651A1 (es) 2000-07-28 2004-06-23 Univ Madrid Complutense Uso de derivados de indol para la manufactura de un medicamento para reducir la presion intraocular y una composicion
JP2002161032A (ja) 2000-09-14 2002-06-04 Taisho Pharmaceut Co Ltd 粘膜適用組成物
CN1390124A (zh) 2000-09-20 2003-01-08 永光制药有限公司 近视眼的预防、治疗药
US20020183279A1 (en) 2001-04-18 2002-12-05 Koichiro Tanaka Pharmaceutical composition containing viscoelastic substance and medication
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
CA2866848C (en) * 2002-07-30 2017-01-03 Omeros Corporation Ophthalmologic irrigation solutions and method
WO2006069213A1 (en) 2004-12-22 2006-06-29 Schering Corporation Pharmaceutical formulations
DOP2007000055A (es) 2006-04-10 2007-10-31 Senosiain S A De C V Lab Composición farmaceutica que comprende un analgésico y vitaminas
AU2008325214A1 (en) 2007-11-08 2009-05-14 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
US9192571B2 (en) 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
CN102413839A (zh) 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
MX2011013061A (es) 2009-06-05 2012-02-28 Aciex Therapeutics Inc Formulaciones oftalmicas de fluticasona y metodos de uso.
US20100311688A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
PT2598119T (pt) 2010-07-29 2018-12-17 Allergan Inc Soluções de brimonidina e timolol isentas de conservantes
EP2739266B1 (en) 2011-08-04 2016-07-27 Omeros Corporation Stable anti-inflammatory solutions for injection
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
KR20160070077A (ko) * 2013-10-03 2016-06-17 임프리미스 파마슈티컬스 인코포레이티드 안구내 투여를 위한 에피네프린-기반 안과용 조성물 및 이의 제조 방법
TWI809304B (zh) 2014-12-01 2023-07-21 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
CN104856990A (zh) 2015-05-07 2015-08-26 武汉武药科技有限公司 去氧肾上腺素酮咯酸溶液及制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
American Optometric Association (Optometric Clinical Practice Guideline, 2010). *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855246B2 (en) 2012-10-24 2018-01-02 Omeros Corporation Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US11234965B2 (en) 2014-12-01 2022-02-01 Omeros Corporation Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
WO2018089467A1 (en) * 2016-11-09 2018-05-17 Beth Israel Deaconess Medical Center, Inc. Methods for reducing recurrence of tumors

Also Published As

Publication number Publication date
US20190175552A1 (en) 2019-06-13
RU2017123221A3 (zh) 2019-06-06
KR20170088875A (ko) 2017-08-02
US20220175727A1 (en) 2022-06-09
BR112017011648A8 (pt) 2022-08-02
CN106999472A (zh) 2017-08-01
AU2015355289A1 (en) 2017-06-22
EP3226857A4 (en) 2018-08-08
TWI809304B (zh) 2023-07-21
MX2022003892A (es) 2022-04-19
NZ732418A (en) 2023-11-24
AR102691A1 (es) 2017-03-15
RU2017123221A (ru) 2019-01-09
CN116077490A (zh) 2023-05-09
EP3226857A2 (en) 2017-10-11
MX2017006829A (es) 2017-09-05
CA2967687A1 (en) 2016-06-09
KR20240046311A (ko) 2024-04-08
HK1244705A1 (zh) 2018-08-17
BR112017011648A2 (pt) 2018-06-26
CL2017001303A1 (es) 2017-12-29
EP3949961A1 (en) 2022-02-09
JP2022145809A (ja) 2022-10-04
IL252559A0 (en) 2017-07-31
WO2016089739A2 (en) 2016-06-09
TW202114657A (zh) 2021-04-16
JP2020079315A (ja) 2020-05-28
JP2018500295A (ja) 2018-01-11
RU2750296C2 (ru) 2021-06-25
TW201620514A (zh) 2016-06-16
US20180280350A1 (en) 2018-10-04
AR119122A2 (es) 2021-11-24
TWI705812B (zh) 2020-10-01
WO2016089739A3 (en) 2016-08-18
AU2015355289B2 (en) 2021-01-21
US11234965B2 (en) 2022-02-01

Similar Documents

Publication Publication Date Title
US20220175727A1 (en) Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
JP6282699B2 (ja) 安定で保存剤非含有の散瞳および抗炎症注射用液剤
JP2019518730A (ja) 眼の炎症性障害および疾患の組合せ処置
JP2007523912A (ja) 眼病変治療用へパリン
RU2744570C2 (ru) Фармацевтическая композиция на основе трамадола для офтальмологического применения
Donnenfeld et al. Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery
RU2694369C2 (ru) Фармацевтическая композиция ибупрофена и трамадола для офтальмологического применения
Uña et al. Perioperative pharmacological management in patients with glaucoma
AU2004249167A1 (en) Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
AlZaid et al. Ocular coherence tomography for the diagnosis of Descemet's detachment after deep sclerectomy and resolution after intracameral air injection
Darwish Exploring the Pathophysiology and Modern Management of Recurrent Retinal Detachment in Silicone Oil-Filled Eyes
Öztürk et al. The efficacy of 2.5% phenylephrine and flurbiprofen combined in inducing and maintaining pupillary dilatation during cataract surgery
Espandar et al. Pharmacologic approaches to the small pupil
DeStafeno et al. I. PERIOPERATIVE MEDICATIONS

Legal Events

Date Code Title Description
AS Assignment

Owner name: OMEROS CORPORATION, WASHINGTON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEMOPULOS, GREGORY A.;FLORIO, VINCENT A.;REEL/FRAME:037833/0457

Effective date: 20160225

AS Assignment

Owner name: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT, TEXAS

Free format text: SECURITY INTEREST;ASSIGNOR:OMEROS CORPORATION;REEL/FRAME:040575/0110

Effective date: 20161103

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: OMEROS CORPORATION, WASHINGTON

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CRG SERVICING LLC;REEL/FRAME:047573/0577

Effective date: 20181115